Intetumumab

Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) [1].

Product Specifications

CAS Number

[725735-28-4]

Product Name Alternative

CNTO 95; Anti-Human CD51 Recombinant Antibody

UNSPSC

12352203

Target

Integrin

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/intetumumab.html

Purity

99.24

Solubility

10 mM in DMSO

Smiles

[Intetumumab]

Molecular Weight

(145.14 kDa)

References & Citations

[1]Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21 (6) :1084-90.